Obiettivo TILC focuses on Innate Lymphoid Cells (ILCs). ILCs are a newly discovered type of lymphocyte, and their study opens up new perspectives for understanding and manipulating of immunity. ILCs include cytotoxic ILCs (NK cells) and helper-like ILCs (ILC1, ILC2 & ILC3). Studies of ILC2 cells have advanced considerably, but much remains unknown about the respective roles of NK, ILC1 and ILC3 cells. TILC aims to explore new frontiers in ILC biology, by focusing on these subsets of ILCs in mice and humans, through five specific aims.1. NK cells, ILC1 & NCR+ILC3 are known to express NKp46 in humans and mice, but the nature of the NKp46 ligands remains unclear, limiting our understanding of the biology of these three major ILC subsets. We thus aim to identify the NKp46 ligands, building on our preliminary data showing that Complement Factor P (CFP, Properdin) is involved in NKp46 recognition, hence revealing an unprecedented mode of immune recognition.2. We also aim to create new mouse models selectively targeting these ILC subsets in vivo. We will then use these models for dissecting out the selective roles of ILC subsets in two major immune functions: cancer surveillance and gut homeostasis. 3. In cancer, we will investigate the contribution of these cells to tumor editing. 4. In the intestine, we will focus on the homeostasis of the cecum and appendix. These organs were long considered to be vestiges of evolution, but our own recent findings and those of phylogenetic studies have challenged this notion. We thus aim to address the role of ILC subsets in the cecum/appendix, and determine whether these organs serve as a refuge for repopulation with commensals after dysbiosis. 5. Finally, we aim to identify patients with deficiencies in ILCs, to dissect the function of these cells in natura.From the molecular scale to that of patients, we believe that TILC will provide answers to some of the most pressing questions concerning the role and clinical potential of NKp46+ ILCs Campo scientifico medical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicinephysiologyhomeostasis Parole chiave Innate Immunity Innate Lymphoid cells Natural Killer cells Programma(i) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Argomento(i) ERC-ADG-2015 - ERC Advanced Grant Invito a presentare proposte ERC-2015-AdG Vedi altri progetti per questo bando Meccanismo di finanziamento ERC-ADG - Advanced Grant Istituzione ospitante UNIVERSITE D'AIX MARSEILLE Contribution nette de l'UE € 2 257 500,00 Indirizzo BOULEVARD CHARLES LIVON 58 LE PHARO 13284 Marseille Francia Mostra sulla mappa Regione Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 2 500 000,00 Beneficiari (2) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto UNIVERSITE D'AIX MARSEILLE Francia Contribution nette de l'UE € 2 257 500,00 Indirizzo BOULEVARD CHARLES LIVON 58 LE PHARO 13284 Marseille Mostra sulla mappa Regione Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 2 500 000,00 Terza parte Soggetto giuridico diverso da un subappaltatore che è affiliato o legalmente collegato a un partecipante. Il soggetto svolge le attività secondo le condizioni stabilite nell’accordo di sovvenzione, fornisce beni o servizi per l’azione, ma non ha sottoscritto l’accordo di sovvenzione. Una terza parte rispetta le regole applicabili al suo partecipante correlato ai sensi dell’accordo di sovvenzione per quanto riguarda l’ammissibilità dei costi e il controllo delle spese. CENTRE HOSPITALIER REGIONAL DE MARSEILLE ASSISTANCE PUBLIQUE-HOPITAUX MARSEILLE Francia Contribution nette de l'UE € 242 500,00 Indirizzo RUE BROCHIER 80 13354 Marseille Cedex 20 Mostra sulla mappa Regione Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Tipo di attività Research Organisations Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 242 500,00